FI3371316T3 - Rokotteita hepatiitti b -virusta vastaan - Google Patents

Rokotteita hepatiitti b -virusta vastaan Download PDF

Info

Publication number
FI3371316T3
FI3371316T3 FIEP16791573.5T FI16791573T FI3371316T3 FI 3371316 T3 FI3371316 T3 FI 3371316T3 FI 16791573 T FI16791573 T FI 16791573T FI 3371316 T3 FI3371316 T3 FI 3371316T3
Authority
FI
Finland
Prior art keywords
hbv
protein
viral vector
nucleotide sequence
hbc
Prior art date
Application number
FIEP16791573.5T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Thomas Monath
Katherine Cohen
Vera Baumgartl-Strasser
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of FI3371316T3 publication Critical patent/FI3371316T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP16791573.5T 2015-11-04 2016-11-03 Rokotteita hepatiitti b -virusta vastaan FI3371316T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250639P 2015-11-04 2015-11-04
PCT/EP2016/076591 WO2017076988A1 (en) 2015-11-04 2016-11-03 Vaccines against hepatitis b virus

Publications (1)

Publication Number Publication Date
FI3371316T3 true FI3371316T3 (fi) 2023-01-13

Family

ID=57249796

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP16791573.5T FI3371316T3 (fi) 2015-11-04 2016-11-03 Rokotteita hepatiitti b -virusta vastaan

Country Status (20)

Country Link
US (2) US11214598B2 (enExample)
EP (2) EP4177348A1 (enExample)
JP (3) JP6914950B2 (enExample)
KR (2) KR20250107977A (enExample)
CN (2) CN108779472B (enExample)
AU (2) AU2016348675B2 (enExample)
CA (1) CA3003557A1 (enExample)
DK (1) DK3371316T3 (enExample)
ES (1) ES2934698T3 (enExample)
FI (1) FI3371316T3 (enExample)
HR (1) HRP20221474T1 (enExample)
HU (1) HUE060648T2 (enExample)
IL (2) IL314371A (enExample)
LT (1) LT3371316T (enExample)
MX (2) MX2018005569A (enExample)
PL (1) PL3371316T3 (enExample)
PT (1) PT3371316T (enExample)
SG (1) SG11201803474UA (enExample)
SI (1) SI3371316T1 (enExample)
WO (1) WO2017076988A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20221475T3 (hr) 2007-12-27 2023-01-06 Universität Zürich Replikacijski defektni vektori arenavirusa
LT3077519T (lt) 2013-12-03 2021-04-26 Hookipa Biotech Gmbh Cmv vakcinos
RS60937B1 (sr) 2014-11-13 2020-11-30 Univ Geneve Tri-segmentirani arenavirusi kao vektori za vakcinu
JP7098330B2 (ja) 2015-06-10 2022-07-11 ホオキパ バイオテック ジーエムビーエイチ Ｈｐｖワクチン
ES2934698T3 (es) * 2015-11-04 2023-02-24 Hookipa Biotech Gmbh Vacunas contra el virus de la hepatitis B
CA3003548A1 (en) 2015-11-12 2017-05-18 Hookipa Biotech Ag Arenavirus particles as cancer vaccines
US10662416B2 (en) 2016-10-14 2020-05-26 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
JP2022010188A (ja) * 2017-02-03 2022-01-14 株式会社三洋物産 遊技機
JP2022010187A (ja) * 2017-02-03 2022-01-14 株式会社三洋物産 遊技機
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
AU2020297011A1 (en) 2019-06-18 2022-02-10 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis B virus (HBV) vaccines and uses thereof
US20220296703A1 (en) * 2019-06-18 2022-09-22 Janssen Sciences Ireland Unlimited Company Cobmination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
LT4037708T (lt) * 2019-09-30 2024-11-25 Gilead Sciences, Inc. Hbv vakcinos ir hbv gydymo būdai
US20220380805A1 (en) * 2019-11-07 2022-12-01 Universität Basel Arenaviruses as vectors
FI4069729T3 (fi) 2019-12-06 2025-04-01 Prec Biosciences Inc Optimoidut muokatut meganukleaasit, joilla on spesifisyys tunnistussekvenssiä varten hepatiitti b -virusgenomissa
KR20220131918A (ko) 2019-12-24 2022-09-29 카나 바이오사이언스, 인코포레이션 다이아실글리세롤 키나제 조절 화합물
EP4121437A1 (en) 2020-03-20 2023-01-25 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
KR102375703B1 (ko) 2020-07-28 2022-03-17 경북대학교 산학협력단 사물 인터넷 환경에서 CoAP 기반의 데이터 스트리밍 방법 및 통신 시스템
US20240174724A1 (en) 2021-03-23 2024-05-30 Hookipa Biotech Gmbh Arenaviruses used in treatments of prostate cancer
WO2022226242A1 (en) * 2021-04-21 2022-10-27 La Jolla Institute For Immunology Engineered arenavirus glycoprotein compositions, methods and use thereof
CN113201051B (zh) * 2021-04-27 2022-08-02 复旦大学 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用
JP2024518558A (ja) 2021-05-13 2024-05-01 ギリアード サイエンシーズ， インコーポレイテッド ＴＬＲ８調節化合物と抗ＨＢＶ ｓｉＲＮＡ治療薬との組合せ
CA3222439A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022297367B2 (en) 2021-06-23 2025-04-10 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
PE20242071A1 (es) 2021-06-23 2024-10-18 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
WO2025056782A1 (en) 2023-09-15 2025-03-20 Hookipa Biotech Gmbh Arenavirus formulations, methods and uses thereof
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH1084967A (ja) 1996-09-19 1998-04-07 Fujirebio Inc Ｂ型肝炎のｅ抗原
EP2351768B1 (en) * 1998-12-04 2014-06-18 Biogen Idec MA Inc. HBV core antigen particles with multiple immunogenic components attached via peptide ligands
FR2803599B1 (fr) * 2000-01-06 2004-11-19 Inst Nat Sante Rech Med Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications
US20100183652A1 (en) * 2002-02-21 2010-07-22 Mark Page STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS
EP1888622A1 (en) 2005-05-23 2008-02-20 Oxxon Therapeutics Ltd. Compositions for inducing an immune response against hepatitis b
CN101037476A (zh) * 2006-03-15 2007-09-19 复旦大学 一种用于制备抗体化乙肝疫苗的融合蛋白及其载体
EP2010537B1 (en) 2006-03-23 2011-12-28 Novartis AG Imidazoquinoxaline compounds as immunomodulators
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
SI2079760T1 (sl) * 2006-12-27 2016-11-30 Emory University Sestavki in metode za zdravljenje okužb
HRP20221475T3 (hr) 2007-12-27 2023-01-06 Universität Zürich Replikacijski defektni vektori arenavirusa
US10076570B2 (en) * 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
WO2011015656A2 (en) * 2009-08-07 2011-02-10 Transgene Sa Composition for treating hbv infection
CA2827150C (en) * 2011-02-12 2018-09-11 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis b infection
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
IN2014DN06118A (enExample) 2012-01-24 2015-08-14 Sanford Res Usd
EP2968506B1 (en) 2013-03-15 2019-07-31 Université de Genève Anti-mycobacterial vaccines
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
LT3077519T (lt) 2013-12-03 2021-04-26 Hookipa Biotech Gmbh Cmv vakcinos
WO2015183895A1 (en) 2014-05-27 2015-12-03 University Of Rochester Novel arenavirus vaccine
US9943585B2 (en) 2014-07-30 2018-04-17 University Of Rochester Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)
JP6875274B6 (ja) 2014-09-22 2021-06-30 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ピチンデウイルスのリバースジェネティクス系及び使用方法
GB201419572D0 (en) 2014-11-03 2014-12-17 Pirbright Inst The Virus
RS60937B1 (sr) 2014-11-13 2020-11-30 Univ Geneve Tri-segmentirani arenavirusi kao vektori za vakcinu
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
JP7098330B2 (ja) 2015-06-10 2022-07-11 ホオキパ バイオテック ジーエムビーエイチ Ｈｐｖワクチン
ES3021881T3 (en) 2015-10-23 2025-05-27 Pasteur Institut Recombinant mopeia virus and vaccine platform
ES2934698T3 (es) * 2015-11-04 2023-02-24 Hookipa Biotech Gmbh Vacunas contra el virus de la hepatitis B
CA3003548A1 (en) 2015-11-12 2017-05-18 Hookipa Biotech Ag Arenavirus particles as cancer vaccines
US10980877B2 (en) 2016-04-28 2021-04-20 The University Of Chicago Method for treating melanoma using lymphangiogenesis inducers and a melanoma-specific antigen
KR20240095333A (ko) 2016-05-18 2024-06-25 유니버시타트 바셀 백신 벡터로서 3개의 세그먼트를 가진 피친드 바이러스
EP3534943A2 (en) 2016-11-04 2019-09-11 Hookipa Biotech GmbH Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
WO2018185307A1 (en) 2017-04-07 2018-10-11 Hookipa Biotech Ag Arenavirus particles to treat solid tumors

Also Published As

Publication number Publication date
EP3371316B1 (en) 2022-10-19
AU2016348675A1 (en) 2018-05-17
JP2018536433A (ja) 2018-12-13
EP4177348A1 (en) 2023-05-10
MX2023013140A (es) 2023-11-28
JP6914950B2 (ja) 2021-08-11
IL259077B2 (en) 2024-12-01
JP7777907B2 (ja) 2025-12-01
HRP20221474T1 (hr) 2023-01-06
NZ781654A (en) 2025-06-27
CN108779472B (zh) 2022-09-09
DK3371316T3 (da) 2023-01-23
CA3003557A1 (en) 2017-05-11
ES2934698T3 (es) 2023-02-24
PT3371316T (pt) 2022-11-17
SG11201803474UA (en) 2018-05-30
IL259077B1 (en) 2024-08-01
AU2016348675B2 (en) 2022-11-17
PL3371316T3 (pl) 2023-02-13
WO2017076988A1 (en) 2017-05-11
JP2024010027A (ja) 2024-01-23
SI3371316T1 (sl) 2023-02-28
MX2018005569A (es) 2018-12-19
LT3371316T (lt) 2022-11-25
KR102832178B1 (ko) 2025-07-11
EP3371316A1 (en) 2018-09-12
US11214598B2 (en) 2022-01-04
CN108779472A (zh) 2018-11-09
IL259077A (en) 2018-06-28
AU2023200108A1 (en) 2023-02-16
HK1255847A1 (en) 2019-08-30
JP2021182922A (ja) 2021-12-02
KR20180082485A (ko) 2018-07-18
KR20250107977A (ko) 2025-07-14
US20220073568A1 (en) 2022-03-10
BR112018009032A2 (pt) 2018-11-06
BR112018009032A8 (pt) 2019-02-26
HUE060648T2 (hu) 2023-04-28
US20180319845A1 (en) 2018-11-08
AU2023200108B2 (en) 2025-08-28
NZ741950A (en) 2023-10-27
IL314371A (en) 2024-09-01
CN115948467A (zh) 2023-04-11

Similar Documents

Publication Publication Date Title
FI3371316T3 (fi) Rokotteita hepatiitti b -virusta vastaan
JP2021182922A5 (enExample)
JP2018536433A5 (enExample)
Rodrigues et al. Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology
Skinner et al. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry
Sánchez-Sampedro et al. The evolution of poxvirus vaccines
US10925946B2 (en) Vaccination methods
HRP20211015T1 (hr) Cjepivo protiv citomegalovirusa (cmv)
JP2017503482A5 (enExample)
JP2017527557A5 (enExample)
Dietzschold et al. New approaches to the prevention and eradication of rabies
JP2017535267A5 (enExample)
US20140079734A1 (en) Methods and Compositions for Alphavirus Replicons
CN104968782B (zh) 利用人副流感2型病毒载体的疫苗
JP2017522907A5 (enExample)
CN104232594B (zh) 重组类禽型h1n1流感病毒灭活疫苗株(js40/pr8)及其制备方法和应用
CN110904153A (zh) 表达非洲猪瘟病毒p12或p17蛋白的重组猪繁殖与呼吸综合征病毒的构建方法及其应用
Li et al. A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice
Maamary et al. Newcastle disease virus expressing a dendritic cell-targeted HIV gag protein induces a potent gag-specific immune response in mice
Zhang et al. Virus-like vesicles based on Semliki forest virus-containing rabies virus glycoprotein make a safe and efficacious rabies vaccine candidate in a mouse model
Lawrence et al. Comparison of heterologous prime-boost strategies against human immunodeficiency virus type 1 Gag using negative stranded RNA viruses
Shoja et al. Formation of self‐assembled triple‐layered rotavirus‐like particles (tlRLPs) by constitutive co‐expression of VP2, VP6, and VP7 in stably transfected high‐five insect cell lines
Wang et al. Parainfluenza virus 5 is a next‐generation vaccine vector for human infectious pathogens
US20150359877A1 (en) Viral Vaccine Vectors
Reguzova et al. A novel multi-antigenic parapoxvirus-based vaccine demonstrates efficacy in protecting hamsters and non-human primates against SARS-CoV-2 challenge